Bellicum Pharmacueticals Inc. (BLCM) Insider David M. Spencer Sells 2,500 Shares
Bellicum Pharmacueticals Inc. (NASDAQ:BLCM) insider David M. Spencer sold 2,500 shares of the stock in a transaction on Tuesday, September 20th. The stock was sold at an average price of $20.01, for a total value of $50,025.00. Following the sale, the insider now owns 173,382 shares in the company, valued at approximately $3,469,373.82. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
David M. Spencer also recently made the following trade(s):
- On Wednesday, July 27th, David M. Spencer sold 10,000 shares of Bellicum Pharmacueticals stock. The stock was sold at an average price of $15.00, for a total value of $150,000.00.
Bellicum Pharmacueticals Inc. (NASDAQ:BLCM) opened at 19.65 on Thursday. The firm has a 50-day moving average price of $18.36 and a 200 day moving average price of $13.19. The firm’s market cap is $531.49 million. Bellicum Pharmacueticals Inc. has a 1-year low of $7.24 and a 1-year high of $23.84.
Bellicum Pharmacueticals (NASDAQ:BLCM) last announced its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported ($0.61) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.57) by $0.04. Bellicum Pharmacueticals had a negative net margin of 21,774.65% and a negative return on equity of 42.22%. During the same period last year, the firm earned ($0.40) earnings per share. Equities analysts predict that Bellicum Pharmacueticals Inc. will post ($2.34) earnings per share for the current year.
Several brokerages have recently commented on BLCM. Piper Jaffray Cos. restated a “buy” rating on shares of Bellicum Pharmacueticals in a report on Saturday, July 9th. Citigroup Inc. upgraded Bellicum Pharmacueticals from a “neutral” rating to a “buy” rating and set a $24.00 target price on the stock in a report on Tuesday, August 9th. Zacks Investment Research cut Bellicum Pharmacueticals from a “hold” rating to a “sell” rating in a report on Thursday, August 11th. Jefferies Group increased their target price on Bellicum Pharmacueticals from $20.00 to $22.00 and gave the stock a “buy” rating in a report on Tuesday, August 9th. Finally, SunTrust Banks Inc. assumed coverage on Bellicum Pharmacueticals in a research note on Thursday, June 2nd. They set a “buy” rating and a $20.00 price target on the stock. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $24.25.
Institutional investors have recently made changes to their positions in the stock. BlackRock Group LTD boosted its position in shares of Bellicum Pharmacueticals by 27.9% in the first quarter. BlackRock Group LTD now owns 12,443 shares of the biopharmaceutical company’s stock valued at $116,000 after buying an additional 2,713 shares in the last quarter. American International Group Inc. boosted its position in shares of Bellicum Pharmacueticals by 106.5% in the second quarter. American International Group Inc. now owns 12,064 shares of the biopharmaceutical company’s stock valued at $156,000 after buying an additional 6,221 shares in the last quarter. Nationwide Fund Advisors boosted its position in shares of Bellicum Pharmacueticals by 141.4% in the second quarter. Nationwide Fund Advisors now owns 13,468 shares of the biopharmaceutical company’s stock valued at $175,000 after buying an additional 7,890 shares in the last quarter. Rhumbline Advisers bought a new position in shares of Bellicum Pharmacueticals during the second quarter valued at $236,000. Finally, Alliancebernstein L.P. boosted its position in shares of Bellicum Pharmacueticals by 24.4% in the second quarter. Alliancebernstein L.P. now owns 19,400 shares of the biopharmaceutical company’s stock valued at $251,000 after buying an additional 3,800 shares in the last quarter. 65.24% of the stock is owned by hedge funds and other institutional investors.
About Bellicum Pharmacueticals
Bellicum Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system.
Receive News & Ratings for Bellicum Pharmacueticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmacueticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.